Granite Point Capital Management L.P. Sells 8,552 Shares of Marinus Pharmaceuticals, Inc. (MRNS)
Granite Point Capital Management L.P. lowered its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 766,448 shares of the biopharmaceutical company’s stock after selling 8,552 shares during the quarter. Granite Point Capital Management L.P. owned 3.49% of Marinus Pharmaceuticals worth $1,050,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC raised its stake in shares of Marinus Pharmaceuticals by 108.1% during the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after purchasing an additional 421,600 shares in the last quarter. Nexthera Capital LP bought a new stake in shares of Marinus Pharmaceuticals during the 1st quarter worth approximately $1,416,000. Finally, KCG Holdings Inc. raised its stake in shares of Marinus Pharmaceuticals by 29.5% during the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 14,692 shares in the last quarter. Institutional investors own 28.76% of the company’s stock.
Marinus Pharmaceuticals, Inc. (MRNS) traded up 0.52% during midday trading on Wednesday, reaching $3.83. The company had a trading volume of 1,232,798 shares. Marinus Pharmaceuticals, Inc. has a 12-month low of $0.82 and a 12-month high of $5.44. The stock’s 50 day moving average is $2.58 and its 200 day moving average is $1.70. The firm’s market capitalization is $99.87 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Equities research analysts expect that Marinus Pharmaceuticals, Inc. will post ($0.74) earnings per share for the current year.
A number of equities research analysts have recently issued reports on the company. ValuEngine upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. JMP Securities reiterated an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday.
Marinus Pharmaceuticals Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS).
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.